135 - Antalgiques

!"#$%&'(%)%*+,-./#0"120#3%.4".56120#3%#"%&'7%)%8905#0-%:+#;%5<#4=.4"%
%
%
%
!481:."194%
>91#%8<.8$1413"-."194%
?9395961#%
@AB%31"0."1943%/.-"1:051C-#3%
D==#"3%148,31-.E5#3%
Antalgique+de+palier+I+
Paracétamol*
F905#0-3%=.1E5#3%G%$98,-,#3%è%
H4".56120#%8#%&C-#%14"#4"194%30-"90"%
8.43%5.%8905#0-%:+-94120#%%
%
D==#"%central%#"%périphérique%%
I-.5#J%-#:".5#J%14K#:".E5#%
%
à%L"1513.E5#%:+#;%=#$$#%#4:#14"#%
%
F,5.1%8<.:"194%'M%$14%)%80-,#%
8<.:"194%NOP+%
• H805"#%Q%'ON6@RN+%
S14"#-T.55#%8#%NOP+UJ%
30K#"%V6,%'6@K%
• D4=.4"%Q%PM$6@W6@RN+%
S14"#-T.55#%NOP+U%
!>%X%&%.4%#"%X%&MW6%Q%
7J($6@W6%"90"#3%5#3%
P+%Y%'M$6@W6@K%
!Z%3,TC-#%Q%¯%$91"1,%S14"#-T.55#%[+U%
%
?D%Q%1430==13.4:#%+,/."120#J%8,40"-1J%
.5:995120#%
\,/."9"9]1:1",%^^^%S_O.:,"`5:`3",14#UJ%
05:C-#J%3.164#$#4"%816J%"9]1:1",%-,4.5#%S!ZHJ%
_*HUJ%\*HJ%"-90E5#%8#%5<+,$93".3#J%
+`/#-3#431E151",%
%
*9]1:1",%.06$#4",#%#4%:.3%8#%/-13#%
:94:9$1".4"#%8<1480:"#0-%#4;`$."120#%
AINS*
F905#0-3%93",9O.-"1:05.1-#3%
S14=5.$$."91-#3J%$1:-9:-13".5514#3J%
59$E93:1."120#UJ%8905#0-3%
"-.0$."120#3J%/93"O9/J%:95120#3%
4,/+-,"120#3J%8`3$,49--+,#3J%
$16-.14#3%
%
H6133#4"%#4%14+1E.4"%5.%aIb&%S"9]1:1",%
816U%#"%aIbR%S"9]1:1",%a>%à%:9]1E3U%
?#-%93%STRES*BONNE*
BIODISPONIBILITEUJ%!cJ%!>J%
/9$$.8#J%6#5%
%
à%H339:1."194%!??%31%dFZ%#"%e%P(.43%
%
F0-,#%5.%/503%:90-"#%/9331E5#%
?9395961#%.%E0"%.4".56120#%
^%=.1E5#%20#%/90-%.4"1O
14=5.$$."91-#%
%
F1==C-#%3#594%H!_f%Sjamais*
à*jeun,*toujours*un*verre*
d’eau,*position*deboutU%
@AB%dD%./-C3%P%$913%8#%6-933#33#%
%
?D%Q%.339:1."194%!DaJ%810-,"120#J%g1"+10$%
S.06%5.%51"+,$1#UJ%c*b%S"9]1:1",%+,$."9UJ%
.4"1:9.605.4"J%H3/1-14#J%a*a%S-1320#%816U%
L5:C-#J%/#-=9-."194%816#3"1T#J%+,$9--.61#J%
.66-.T."194%8<04#%81T#-"1:0593#J%.49-#:"1"#3J%
E-050-#3%.4.5#3J%!ZH%=94:"1944#55#J%-,"#4"194%
+`8-9O398,#J%+`/#-W.51,$1#J%4,/+-9/."+1#%
14"#-3"1"1#55#J%4,:-93#%/./155.1-#J%:0".4,#%
SE,414%90%g`#55UJ%.3"+$#J%h014:W#J%./5.31#%
$,8055.1-#J%+,/."9"9]1:1",J%4#0-9O/3`J%
"+-9$E93#%.-",-1#55#%%
Néfopam*
F905#0-3%$98,-,#3%G%3,TC-#3%S/.3%#4%
:+-94120#U%
%
H4".56120#%494%$9-/+14120#%Snon*
opioïdeU%8<.:"194%centrale%S/.3%.4"1O
14=5.$$."91-#%41%.4"1/`-,"120#U%
!c%90%!>%%
%
Pas*de*preuve*sur*la*voie*orale*
RM$6@R%$g%S14"#-T.55#%8#%
P+%31%!c%@%N+%31%!>U%$.]%&RM%
$6%@RN+%%
a!%Q%dD%#"%#4=.4"%X%&(.43%
%
?D%Q%"E%-`"+$#%:.-81.20#J%.8,49$#%
/-93"."120#J%iHdH%
\`/#-308."194J%ZHLJ%".:+`:.-81#J%:94=03194J%
convulsionJ%T#-"16#3J%_@>J%:,/+.5,#J%
39$495#4:#J%3C:+#-#33#%E0::.5#%
S?.3%8#%8,/-#33194%-#3/1-."91-#J%41%8#%
-.5#4"133#$#4"%80%"-.431"U%
%
%
%
%
%
%
%
%
%
(thrombocytopénie)
mydriase

!"#$%&'(%)%*+,-./#0"120#3%.4".56120#3%#"%&'7%)%8905#0-%:+#;%5<#4=.4"%
%
Antalgique+de+palier+II+
a98,14#%
F905#0-3%$98,-,#3%G%
14"#43#3%8<#$E5,#%90%
4#%-,/948.4"%/.3%.0%
/.51#-%!%S8905#0-3%.160#3%
90%:+-94120#3U%
f#05%S81+`8-9:98,14#%#4%g!%90%g?U%90%.339:1."194%
.T#:%?.-.:,".$95%
%
I/19j8#%4."0-#5J%$,".E951"#%201%.%04#%.:"1T1",%
.4.56,3120#k%*-.43=9-$,%#4%c9-/+14#%/.-%al?%RFP%
'MMOPMM$6%S894"%RMO(M$6%
8#%:98,14#U%à%&OR:/%
"90"#3%PO[+%S&(MO&[M$6%8#%
:98,14#%@%'6%8#%
?.-.:,".$95%@%RN+U%
?D%Q%dDJ%V6,%
%
a!%Q%X%&R.43J%X%&[.43%31%.$`68.5#:"9$1#%
@%.8,49j8#:"9$1#%!Z#3/J%.3"+$#J%!\a%
3,TC-#J%.55.1"#$#4"J%.339:1,%.69413"#3@%
.4".69413"#3%$9-/+14120#3%
f,8."194J%T#-"16#3J%:943"1/."194J%4.03,#3@%>J%
E-94:+93/.3$#J%ZHLJ%8,/#48.4:#J%
3`48-9$#%8#%3#T-.6#%
%
à%f0-893.6#%Y%_.59]94#*
Opium*
Lamaline,+Izalgi+
H339:1."194%?.-.:,".$95%S"90"#3%5#3%N+U%
%
?D%Q%V6,%%
%
a!%Q%!Z#3/J%!\a%3,TC-#J%.55.1"#$#4"J%
.339:1,%.69413"#3@%.4".69413"#3%
$9-/+14120#3%
Tramadol*
g?%S&R+%90%RN+U%m%14"#-893#%
g!%SNOP+U%m%.339:1,%.0%?.-.:,".$95%
à%>91#%!>%+93/1".51C-#%
%
I/19j8#%synthétique%8<.:"194%centrale%$1]"#%
S$,".E9513$#%/.-%5#%al?RFPU%
Agoniste%8#3%-,:#/"#0-3%morphiniques*mu%#"%
inhibiteurs*de*la*recapture*de*la*sérotonine*et*
noradrénaline%
F93#%$.]%Y%NMM$6@K%
%
?D%Q%V6,J%:94801"#%T,+1:05#J%:94"-n5#%
/931"1=%.0%89/.6#J%.""#4"194%
.0"9$,81:."194%/.-%?.-.:,".$95%31%
=9-$#%.339:1,#%
%
?#0"%o"-#%0"1513,%:+#;%5.%dD%
%
a!%Q%X%'.43%S&(.43%31%g!%@%&R%.43%31%g?UJ%
épilepsie%494%:94"-n5,#J%.339:1,%!cHI%
#"%.69413"#3@%.4".69413"#3%
$9-/+14120#3J%!Z#3/J%!\a%3,TC-#J%.5:995%
f,:+#-#33#%E0::.5#J%8905#0-3%.E89$14.5#3J%
4.03,#3J%:943"1/."194J%:,/+.5,#J%T#-"16#3J%
"-90E5#3%T130#53J%:94T0531943J%39$495#4:#J%sd*
sérotoninergique%S$,".E9513#0-3%5#4"3UJ%
8,/#48.4:#J%38%8#%3#T-.6#%Sexcès*d’activité*
opioïde%:+#;%$,".E9513#0-3%-./18#3U%
%
%
D==1:.:1",%8<04%.4".56120#%Q%E.133#%'M%$$%30-%5<D>H%#4%.160#%@%E.133#%&M%$$%30-%D>H%#4%:+-94120#%%
%
PAS*d’association*palier*II*et*palier*III*
%
D>H%e%P@&M%Q%-#:90-3%.0%/.51#-%!!!%8<#$E5,%
%
%
%
%
%
%
%
%

!"#$%&'(%)%*+,-./#0"120#3%.4".56120#3%#"%&'7%)%8905#0-%:+#;%5<#4=.4"%
%
%
%
!481:."194%
>91#%8<.8$1413"-."194%
a94"-#O1481:."194%
D==#"3%148,31-.E5#3%
Antalgique+de+palier+III+(opioïdes+forts)+=+agonistes+purs+
Morphine*
F905#0-3%3,TC-#3%:.4:,-#03#3%#"%494%:.4:,-#03#3%%
Chlorhydrate%8#%$9-/+14#%Q%faJ%!cJ%!>J%/,-180-.5#J%
14"-."+,:.5%
Sulfate%8#%$9-/+14#%S3W#4.4U%Q%/#-%93%Sg?%90%g!U%
à%F0-,#%$.]%7K%3.0=%/9$/#%R[K%#"%f05=."#%8#%$9-/+14#%
%
*+,9-120#$#4"%/.3%8#%893#%/5.=948%$.]%
O !430==13.4:#%-#3/1-."91-#%
8,:9$/#43,#%
O !430==13.4:#%+,/."9O
:#5505.1-#%3,TC-#%
O !430==13.4:#%-,4.5#%
3,TC-#%
O D/15#/31#%494%:94"-n5,#%
O *aJ%\*!a%
O !4"9]1:."194%.5:995120#%
.160#%#"%F*%
O H339:1."1943%!cHI%%
O H339:1."1943%.69413"#3%
.T#:%.69413"#3O
.4".69413"#3%#"%
.69413"#3%/.-"1#53%%
O a943"1/."194%S/#-313"#%^^^U%
à%g.]."1=3%flf*DcH*!hLD%
O _@>%S#3"9$/#%RO'3U%à%.4"1O
,$,"120#%/8"%[O&(K%S:0-."1=%Q%
4#0-95#/"120#%8<.:"194%
:#4"-.5#J%:9-"1:9j8#3J%
3,"-943J%.4".69413"#3%(O\*'J%
8-9/#-1895U%
O f9$495#4:#%%
O F,/-#33194%-#3/1-."91-#%SX%
&M@$14U%à%-,.J%_.59]94#%
S3164#%8#%30-893.6#U%
O *E%:9641"1=3J%:94=03194%S3164#%
8#%30-893.6#U%
O F`30-1#J%ZHL%
O ?-0-1"%
O f,:+#-#33#%E0::.5#%
O *95,-.4:#%#"%8,/#48.4:#%S38%
8#%3#T-.6#%.%5<.--o"U%à%
-#:+#-:+#-%dFZ%8#%$,303.6#%
Y%I/198%Z13W%*995%
%
%
f164#%8#%30-893.6#%Y%%
O Somnolence%SDFf%e%&U%
O Bradypnée*SdZ%X%&M@$14%Y%ZR%
90%Z'U%
O c`9313%%
O c`9:5941#3%
%
Hydromorphone*
%
%
F905#0-3%cancéreuses%#4%:.3%8#%-,313".4:#%90%
14"95,-.4:#%.0]%9/19j8#3%=9-"3%S2ème*INTENTIONU%
f9/+1894#%Q%/#-%93%S8,5.1%8<.:"194%YR+J%80-,#%8<.:"194%Y%&R+U%
%
à%F0-,#%$.]%R[K%
Oxycodone*
F905#0-3%3,TC-#3%:.4:,-#03#3J%8905#0-3%.16p#3J%
8905#0-3%4#0-9/."+120#3%S/503%/0133.4"%20#%5.%
$9-/+14#U%
I]`:94"14J%I]`49-$J%I]`49-$9-9Q%/#-%93%S$.]Q%R[KU%
g?%S12hU%90%g!%S4hU%
I]`49-$%Q%!>%S$.]%Q%7KU%
à%H8./",%#4%:.3%!Z%SG%/-,=,-#-%31%!ZU%
Fentanyl*
&MM%=913%/503%/0133.4"%20#%c9-/+14#%
%
*F%Q%8905#0-3%3,TC-#3%:.4:,-#03#3%#"%494%:.4:,-#03#3%
*c%Q%.::C3%890590-#0]%paroxystique%avec*TT*de*fond%
8.43%8905#0-3%cancéreuses*S:+#;%8#3%/."1#4"3%-#:#T.4"%
8#3%9/19j8#3%PM%$6%8#%$9-/+14#%9-.5#@K%8#/013%e%&%3U%
*-.438#-$120#%Q%F0-96#31:%S$.]%Q%R[K%=&NKU%à%.:"194%8#%72h*
%
*-.43$020#03#%Q%$.]%R[K%=7K%à%.:"194%8#%1-2h*S/9331E151",%
8#%-,.513#-%04#%"1"-."194U%
%
à%H8./",%#4%:.3%!Z%SG%/-,=,-#-%31%!ZU%
Méthadone*
*-.1"#$#4"%30E3"1"0"1=%8#3%/+.-$.:9O%8,/#48.4:#3%
%
c.]%&N+%=7K%
%
Agonistes+
partiels+
Buprénorphine*
*-.1"#$#4"%30E3"1"0"1=%8#3%/+.-$.:98,/#48.4:#3%
S=9-"#3%893#3U%
%
è%?.3%:5.33,%:9$$#%3"0/,=1.4"%/-#3:-1/"194%/.-%"90"%
$,8#:14%
Effet*plafondJ%/#0%3#431E5#%G%5.%_.59]94#%
%
c.]%R[K%=7K%
Agonistes+/+
antagonistes+
Nalbuphine*
H4".69413"#%$0J%.69413"#%W.//.%
%
L"1513."194%#4%pédiatrie%%
Se%&[%$913U%
L"1513#-%/90-%prurit*lié*aux*opiacé%
H339:1."194%.0]%9/19j8#3%=9-"3%a!%
Effet*plafondJ%80-,#%8<.:"194%:90-"#J%04120#$#4"%!>%90%
-#:".5%S/.3%?IU%
%
%

!"#$%&'(%)%*+,-./#0"120#3%.4".56120#3%#"%&'7%)%8905#0-%:+#;%5<#4=.4"%
%
!
Généralités*
Equivalence*
Règles*de*prescription*
Particularité*
Morphine+
O I/1.:,#%Y%
30E3".4:#%
4."0-#55#%
O I/19j8#%Y%
4."0-#55#%#"%
3`4"+,"120#%%
%
_1T#.0]%8<.:"1943%
O a,-,E-.5%
O c,8055.1-#%
O ?,-1/+,-120#%
&%$9-/+14#%?I%Y%P$6%8#%a98,14#%
&%$9-/+14#%?I%Y%($6%8#%*-.$.895%
&%$9-/+14#%?I%Y%q%$9-/+14#%fa%%%
&%$9-/+14#%?I%Y%&@'%$9-/+14#%!>%%
&%$9-/+14#%!>%Y%&%I]`:9894#%fa@%!>%
&%I]`:9894#%?I%Y%q%I]`:9894#%fa@%!>%
&%$9-/+14#%?I%Y%q%I]`:9894#%?I%
&%$9-/+14#%?I%Y%&@7J(%\`8-9$9-/+94#%?I%%
&%$9-/+14#%?I@RN+%Y%&@RJN%=#4".4`5%"-.438#-$120#@7R+%
PM$6%$9-/+14#%?I%Y%R(06%=#4".4`5%/.":+%
O I-8944.4:#%sécuriséeJ%/-,:13#-%$95,:05#J%
/9395961#J%=-,20#4:#%#4%toutes*lettresJ%
/-,:13#-%5#%49$E-#%8#%:9$/-1$,3%
O Présenté*dans*les*24h%/90-%-,:0/,-#-%5.%
893#%:9$/5C"#%%
O F0-,#%8#%/-#3:-1/"194%7%K90-3%31%IV%
O F0-,#%8#%/-#3:-1/"194%8#%R[%K%Q%.T#:%
=-.:"1944#$#4"%*c%7K%@%&NK%*F%
O F0-,#%8#%/-#3:-1/"194%8#%R[%K%/90-%?I%%
O ?-#3:-1/"194%8<.4".69413"#%3`3",$."120#%%
?.3%8<9/19j8#%=9-"%8.43%5#3%
8905#0-3%8`3=94:"19444#55#3%
%
HT13%3/,:1.513,%Q%
O H0O8#5G%8#%3*mois*
O >*150mg*/j*
O F905#0-%14#]/5120,#%
O h01%/#-313"#%$.56-,%"%893#%
O a9$9-E181",%/3`:+1."-120#%
O dFZ%$,303.6#%
%
F0-,#%8<.:"194%Q%g?%Y%&R+%@%g!%Y%N+%@%/.":+%Y%7R+%@%"-.43$020#0]%Y%&OR+%
%
Titration*:*obtenir*une*EVA*<*4/10*
Titration*par*voie*orale*
*1"-."194%/.-%T91#%!>%
?aH%
Titration*avec*opioïde*à*LI*
Titration*avec*opioïde*a*LP*
O F93#%141"1.5#%Q%10mg%%
O _94%3905.6,%Q%.06$#4"."194%&M$6%S&+%
14"#-T.55#U%&M$6%]%P@K%
O H%RN+%Q%.06$#4"."194%8#%5.%893#%%
O H%N[O7R+%Q%31%,20151E-,%/.33.6#%.%g?%
O F93#%141"1.5#%Q%30mg/*12h*=*60mg/24h*
S/9331E151",%8<14"#-893#%8#%&@P%G%&@&M%80%
g?U%Q%&$6@W6@K%
O H8./"."194%.0%E90"%8#%RN+%S.K03"#$#4"%31%
^%8#%N%14"#-893#3U%
O H$/905#%8#%a+59-+`8-."#%8#%$9-/+14#%S&M$6%
8#%$9-/+14#%G%&M$g%8<#.0U%
O ?9395961#%$.]%Y%MJM($6@W6%G%MJ&($6@W6%
O !>F%Q%1-3mg%"90"#3%5#3%5-10min%K0320<G%
3,8."194%8#%5.%8905#0-%%
O ?-#3:-1/"194%Q%F,E1"%:94"140%
8#%$9-/+14#J%/9395961#%8#3%
E9503J%/,-198#%-,=-.:".1-#%
S7$14%#4%6,4,-.5U%
%
%
%
%
%
%
%
%
Indications*de*la*TENS*Q%
?."1#4"3%390==-.4"%8#%8905#0-3%:+-94120#3%%
O!430==13.4:#%90%14.8,20."194%8#3%"-.1"#$#4"3%$,81:.$#4"#0]%%
O?-,3#4:#%8<04%49$E-#%30==13.4"%8#%=1E-#3%$`,51413,#3%G%3"1$05#-%#"%/."1#4"%-,/948.4"%G%5.%
4#0-93"1$05."194%%
Oc9"1T,%#"%9E3#-T.4"%%
O?9331E151",%#"%:./.:1",%8#%=9-$#-%5#%/."1#4"%G%5.%"#:+4120#%%
R%"`/#3%Q%+.0"#%=-,20#4"#%S.4.56,31#%-./18#%201%4#%/#-313"#%/.3U%#"%E.33#%=-,20#4:#%S.4.56,31#%201%/#-313"#U%
a!%Q%6-933#33#J%"+-9$E93#%T#14#03#%90%.-",-1#55#J%?cJ%/.3%8.43%5.%-,6194%:#-T1:.5#%
%
Indication*à*la*stimulation*médullaire*Q%%
OF905#0-3%:+-94120#3%8<9-1614#%4#0-9/."+120#J%./-C3%,:+#:%8#3%
.5"#-4."1T#3%"+,-./#0"120#3%3#:948.1-#3%G%04%3`48-9$#%890590-#0]%
:+-94120#3%-.81:05.1-#3%90%"-94:05.1-#%8<9-1614#%81.E,"120#J%
;93",-1#44#J%"-.0$."120#3%90%:+1-0-61:.5#%/#-313".4"%8#/013%e%&%.4%90%
fZFa%e%P%$913%
OF905#0-3%:+-94120#3%8<9-1614#%13:+,$120#%./-C3%,:+#:%8#3%
.5"#-4."1T#3%"+,-./#0"120#3%3#:948.1-#3%G%5.%$.5.81#%8#%r0#-6#-%
DhZ%Q%%
OZM%Q%-#3/1-."194%49-$.5#J%dZ%e%&M@$14%
OZ&%Q%-94=5#$#4"J%dZ%e%&M@$14%
O
ZR%Q%-#3/1-."194%1--,6051C-#%#"@90%dZ%X%&M@$14%
OZ'%Q%/.03#3%90%./4,#%
DFf%Q%%
ODFfM%Q%/."1#4"%,T#155,%
ODFf&%Q%39$495#4"J%=.:15#$#4"%-#T#155.E5#%
O
DFfR%Q%39$495#4"J%-#T#155.E5#%/.-%3"1$05."194%T#-E.5#%%
ODFf'%Q%39$495#4"J%-#T#155.E5#%/.-%3"1$05."194%".:"15#%

!"#$%&'(%)%*+,-./#0"120#3%.4".56120#3%#"%&'7%)%8905#0-%:+#;%5<#4=.4"%
%
Douleurs%neuropathiques*(traitement*d’au*moins*6*mois,*prise*systématique)%
&C-#%14"#4"194%
RC$#%14"#4"194%
'C$#%14"#4"194%
O H4"18,/-#33#0-3%tricycliques%SaI_*!_LDU%
O Antiépileptiques%8#%5.%:5.33#%8#3%gabapentinoïdes%S?HZIblf*!hLDU%
O H4"18,/-#33#0-3%$1]"#3%!Zf_.%Q%81.EC"#%^^%
O D$/5."-#%8#%5189:.j4#%SY%/.":+%8#%>#-3."13U%Q%8905#0-3%59:.513,#3%à%8905#0-%/93"O;93",-1#44#%%
O *D_f%
O H339:1."194%8#3%"-.1"#$#4"3%8#%&C-#%14"#4"194%
O a./3.j4#%+.0"#%:94:#4"-."194%S8905#0-3%
59:.513,#3U%
O *-.$.895%
O c9-/+14120#3%=9-"3%
O f"1$05."194%:,-,E-.5#%
S$,8055.1-#U%
O F-#;9"9$1#%
%
*
Molécule*
Action*
Indications*
Effets*secondaires*
Antidépresseurs*
*-1:`:5120#%
Amitriptyline+(10-25mg+le+soir)%
O !4+1E1"194%-#:./"0-#%8#%
49-.8-,4.514#%#"%3,-9"9414#%
O H4"1:+9514#-6120#%
O H4"1+13".$14120#%
O Neuropathies*périphériques%#"%:#4"-.5#3%
O ?-,T#4"194%céphalée%8#%tension%90%migraines%
O a9O.4.56#31#%8.43%5.%59$E.561#%:+-94120#%90%=1E-9$`.561#%
O f,8."194J%3#43."194%T#-"1614#03#%
O r90:+#%3C:+#J%:943"1/."194%
O \`/9"#43194%9-"+93"."120#%
O *-90E5#%80%-`"+$#%:.-81.20#%
%
a!%Q%iHdHJ%\r?%
!Zf_.%
Venlafaxine+(37,5mg+le+matin)J%
duloxétine+milnacipram+%
O !4+1E1"194%-#:./"0-#%8#%
49-.8-,4.514#%#"%3,-9"9414#%
?.3%8<#==#"%.4"1:+9514#-6120#%#"%
.4"1+13".$14120#%
O F905#0-3%:+-94120#3%4#0-9/."+120#3%
O ?-9/+`5.]1#%8#%5.%$16-.14#%
O Fibromyalgie%SF059],"14#J%c154.:1/-.$U%
O _.03,#J%\*HJ%/-9O.-`"+9$6C4#%S>#45.=.]14#U%
O \,/."9"9]120#%SF059],"14#U%
O _.03,#%Sc154.:1/-.$U%
!fZf%
%
O !4+1E1"194%-#:./"0-#%8#%
49-.8-,4.514#%#"%3,-9"9414#%
c9143%#==1:.:#%20#%*-1:`:5120#%#"%!Zf_.%%
a9%$9-E181",%8,/-#331T#%#"%.:"194%30-%5.%"+`$1#%%
O F16#3"1=3%%
O f8%3,-9"9414#-6120#%%
O !4+1E1"#0-3%80%al?%N(M%
Antiépileptiques*
a5.33120#%
Carbamazépine,+Clonazépam,+
phénytoïne,+valproate+de+sodium%
%
O _,T-.561#%"-16,$14.5#%#33#4"1#55#%
O F905#0-3%4#0-9/."+120#3%
%
_90T#55#%6,4,-."194%
Gabapentinoïdes*Q%Gabapentine,+
Prégabaline+
%
O Première*intention*et*référence*dans*douleur*neuropathique*S?-,6.E.514#%
/90-%8905#0-3%centraleU*
O F905#0-3%3/94".4,#3%:94"140#%90%/.-9]`3"120#%
O ?+,49$C4#%.5598`4120#%
O H:"194%+`/49"120#%S$#155#0-%39$$#15UJ%.339:1."194%9/19j8#@%"-1:`5120#%#4%RC$#%
14"#4"194%
f#43."194%T#-"1614#03#J%3,8."194J%.".]1#%59:9$9"-1:#%%
O ?-13#%8#%/9183%Si.E./#4"14#U%
H0"-#3%Q%lamotrigine,+oxcarbazépine,+
topiramate,+lévétiracétam*
%
D4%RC$#%90%'C$#%14"#4"194%90%14"95,-.4"3%.0]%$95,:05#3%8#%&C-#%14"#4"194%
O g.$9"-1614#%Q%/95`4#0-9/."+1#%81.E,"120#J%H>a%
O I]:.-E.;,/14#%Q%8905#0-%.%:9$/93.4"#%/.-9]`3"120#%
O *9/1-.$."#J%5,T,"1-.:,".$%Q%,:+#:%90%14"95,-.4:#%&C-#%14"#4"194%
%
%
%
%